Login
Innoviva, Inc. logo

Innoviva, Inc.

inva.com

What Do They Do?

Collects royalties from a pharmaceutical partner on respiratory medicines and sells critical-care and infectious-disease medicines for hospital care, alongside strategic healthcare investments.

Who Are Their Customers?

GSK pays royalties on partnered respiratory medicines. Hospitals, health systems and government facilities are end users of Innoviva’s medicines, with distributors involved in some sales.

Do Revenues Turn Into Profits?

Yes. It kept 66 cents of every revenue dollar as net income in FY2025 and turned 48 cents into free cash flow.

Operating income, FY2025
40% of revenue
▼ −2% vs FY2024 ($166.9M, 47%)
Net income, FY2025
66% of revenue
▲ +1059% vs FY2024 ($23.4M, 7%)
Free cash flow, FY2025
48% of revenue
▲ +4% vs FY2024 ($188.4M, 53%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −2%
vs $107.8M in Q3 FY2025
Net income
▼ Turned to a loss
vs $89.9M in Q3 FY2025
Royalty Revenue share of revenue vs 55.6% in Q3 FY2025
  • Aug 5, 2026 Gave 2026 U.S. sales guidance and licensed XACDURO for new markets The company said it remained on track for at least $150 million in IST U.S. sales in 2026 and licensed XACDURO for several markets.

Broader commercial portfolio The hospital and infectious-disease business has broadened from GIAPREZA and XERAVA as marketed products, with SUL-DUR in development, to a wider commercial portfolio that includes XACDURO, ZEVTERA and NUZOLVENCE.

Revenue over time
Royalty Revenue Net product sales License and other revenue License revenue
$500M$250M$0

Who Do They Compete With?

Competes with GSK, AstraZeneca, TEVA, Boehringer Ingelheim, Merck, Novartis, Sunovion, Chiesi, Genentech, Sanofi Genzyme, and Amgen

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support